NEW YORK, Jan. 18, 2017 /PRNewswire/ -- Harwood Feffer LLP
(www.hfesq.com) is investigating potential claims against the board
of directors of CoLucid Pharmaceuticals, Inc. ("CoLucid" or the
"Company") (NASDAQ: CLCD) concerning the proposed acquisition of
the Company by Eli Lilly and Company ("Eli Lilly").
Under the terms of the offer, Eli Lilly would acquire CoLucid in
a transaction valued at approximately $960
million. Pursuant to the terms of the transaction,
CoLucid shareholders would receive $46.50 in cash per share owned. One Wall
Street analyst set a price target for CoLucid shares of
$58 per share.
Our investigation concerns whether the CoLucid board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
stockholders.
If you own CoLucid shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Robert I. Harwood, Esq.
Benjamin I. Sachs-Michaels, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Follow us on Twitter: @HarwoodFeffer
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the
firm.
Attorney Advertising. The law firm responsible for this
advertisement is Harwood Feffer LLP (www.hfesq.com). Prior
results do not guarantee or predict a similar outcome with respect
to any future matter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/harwood-feffer-llp-announces-investigation-of-colucid-pharmaceuticals-inc-300393031.html
SOURCE Harwood Feffer LLP